Protection of Escherichia coli against UV damage by R factor 1818 was independent of host cell-mediated excision, recombination, or reinitiation repair mechanisms.Treatment with chloramphenicol after UV irradiation abolished protection by R-1818, suggesting that a protein formed after the cell is damaged mediates R factor induced protection.

01 Nov 1974·Journal of General Microbiology

Envelope Alterations Produced by R Factors in Proteus mirabilis

Article

Author: HESSLEWOOD, S. R. ; SMITH, J. T.

SUMMARY: R-1818 increases swarming and abolishes proteolytic enzyme excretion by P. mirabilis F67. R-TEM reduces swarming, increases proteolytic enzyme excretion by this organism and renders it susceptible to sodium deoxycholate. The properties of strains harbouring both R-1818 and R-TEM simultaneously are dependent on the order of introduction of the R factors, the R factor first present being dominant. Recombination between the R factors in this organism does not seem to be responsible for these observations.

01 Aug 1972·Journal of BacteriologyQ3 · BIOLOGY

R Factor Elimination During Thymine Starvation: Effects of Inhibition of Protein Synthesis and Readdition of Thymine

Q3 · BIOLOGY

Article

Author: Smith, J. T. ; Pinney, R. J.

R factor 1818 is shown to be eliminated from a thymineless strain of Escherichia coli J6-2 (R-1818) during thymine starvation. Readdition of thymine to the starved cultures produces a partial recovery in viable count but does not affect the proportion of R − cells. The R factor is not cured from exponential- or stationary-phase cultures which are starved of required amino acids as well as thymine, nor from cells which are deprived of thymine in the presence of chloramphenicol. However, in both of these cases, the extent of thymineless death is reduced. It is suggested that protein synthesis is a requirement for R-1818 elimination, and the possible nature of this protein is discussed.

100 Deals associated with SF-1019

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	Malaysia	Argyll Biotechnologies LLC	10 Aug 2008
Diabetic Neuropathies	Malaysia	Argyll Biotechnologies LLC	09 Aug 2008
Skin Ulcer	Malaysia	Argyll Biotechnologies LLC	31 Jul 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Neuropathies	Phase 1	-	Argyll Biotechnologies LLC	-
Diabetic Neuropathies	Phase 1	-	Immunosyn Corp.	-
Inflammation	Phase 1	-	Argyll Biotechnologies LLC	-
Inflammation	Phase 1	-	Immunosyn Corp.	-
Skin Ulcer	Phase 1	-	Argyll Biotechnologies LLC	-
Skin Ulcer	Phase 1	-	Immunosyn Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

SF-1019

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation